GVK Biosciences (GVK BIO) announced it has expanded its database of clinical biomarkers (GOBIOM) has enabled the Group to the characterization of biomarkers of U.S. Food and Drug Administration (FDA).
The database GOBIOM has the latest information and updates on all the biomarkers reported in several preclinical and clinical studies will be extremely useful in the process of FDA biomarker qualification, according to a company announcement.
GOBIOM the database is a complete collection of all biomarkers evaluated clinical and preclinical exploration related to various therapeutic areas reported in the global clinical trials, clinical and preclinical.
12.000 GOBIOM contains information on biomarkers, including biochemical, genomics, imaging, metabolite, cellular and physiological markers of multiple data points on experimental data, analytical, clinical and statistical skills in various medical interventions.
Sreen Devidas, Vice President, Sales & Marketing, Information Technology said, "with the USFDA Gvk BIO helped to develop safety biomarker content GOBIOM. Interconnectivity between drug toxicity, dose, and the population has been one of emphasizing the pre-clinical qualification. Biomarker analysis tools included in the database so that you can make a comparative analysis of biomarkers of interest."
Monday, April 25
GVK BIO Database Of Biomarkers By The FDA Group
Subscribe to:
Post Comments (Atom)
0 Comments:
Post a Comment